Article
Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand.
Clinical therapeutics - 1 Jul 2009
Vannaprasaht Suda, Angsuthum Susothorn, Avihingsanon Yingyos, Sirivongs Dhavee, Pongskul Cholatip, Makarawate Pattarapong, Praditpornsilpa Kearkiat, Tassaneeyakul Wongwiwat, Tassaneeyakul Wichittra
Abstract excerpt
BACKGROUND: Thiopurine S-methyltransferase (TPMT) is a polymorphic enzyme associated with detoxification of azathioprine, an immunosuppressant used after renal transplantation in several Asian countries. Patients with variations of the TPMT gene may be at risk for myelosuppression after they receive a standard dosage of the drug. The frequency of TPMT*3C has been reported to be higher in the Thai population than...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
